FDC Q4 FY26 Revenue Surges 18.9% to ₹585 Crore, Profit Soars 167.4%
FDC Limited reported Q4 FY26 consolidated revenue of ₹585 crore, up 18.9% YoY. PAT surged 167.4% to ₹103 crore. Full-year FY26 revenue was ₹2,171 crore. The US business saw significant growth, and the company received U.S. FDA approval for Fluconazole Tablets.
The substantial growth in revenue and profit, coupled with a significant increase in EBITDA and a key regulatory approval, are material events that will likely have a high impact on investor sentiment and the company's valuation.
The company reported strong year-on-year growth in revenue and significant profit increase for the quarter and fiscal year, along with positive regulatory news (FDA approval).
FDC Limited announced its financial results for the fourth quarter and year ended March 31, 2026. The company reported a consolidated revenue from operations of ₹585 crore for Q4 FY26, an increase of 18.9% year-on-year. This growth was driven by strong performance across all three business segments: Domestic Formulations grew by 8.5%, Export Formulations by 99.3%, and API business by 38.6%.
For the full fiscal year FY26, revenue from operations stood at ₹2,171 crore, marking a 3.0% growth compared to FY25. The company's EBITDA for Q4 FY26 was ₹106 crore, with margins at 18.2%, a significant improvement from 11.0% in the previous year. For FY26, EBITDA was ₹346 crore with margins at 15.9%.
Profit After Tax (PAT) for Q4 FY26 surged by 167.4% to ₹103 crore, with Earnings Per Share (EPS) at ₹6.35. For FY26, PAT stood at ₹281 crore, a 5.5% increase, and EPS was ₹17.29.
The US business showed a robust performance in Q4 FY26, with revenue from supplies at ₹71 crore, a year-on-year growth of 165.1%. Overall US business revenue grew by 46.9% year-on-year.
Domestically, the Formulations business achieved revenue of ₹452 crore in Q4 FY26, an 8.5% year-on-year growth. For FY26, domestic sales were ₹1,781 crore. Export Formulations sales in Q4 FY26 were ₹89 crore, a 99.3% year-on-year increase, contributing 15% to consolidated sales. For FY26, Export Formulations sales were ₹260 crore, a 23.5% growth.
The API business registered sales of ₹42 crore in Q4 FY26, up by 38.6% year-on-year, contributing 7% to consolidated sales. For FY26, the API business grew by 8.5% with sales of ₹121 crore.
During the quarter, FDC Limited received U.S. FDA approval for Fluconazole Tablets USP 50mg, 100mg, 150mg, and 200mg.
What to do with a filing like this
FDC Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by FDC Limited. Read the original for the full detail.